We are a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system, starting with painful diabetic neuropathy, fibromyalgia, PTSD and Parkinson’s cognitive impairment. We have a proven platform for discovering proprietary compounds that works through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our pipeline of novel clinical candidates to treat indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more about our company or rewarding career opportunities, please visit our website at www.aptinyx.com or follow us on Twitter @Aptinyx
Location: United States, Illinois, Evanston
Employees: 51-200
Total raised: $135M
Founded date: 2015
Investors 13
Show more
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.12.2017 | Series B | $70M | Bain Capit... |
| 10.05.2016 | Series A | $65M | - |
Mentions in press and media 31
| Date | Title | Description | Source |
| 12.08.2022 | Bolt throws a wrench in the pipeline, looking to conserve ... | A meltdown in the biotech market is making most execs cautious, including Bolt Biotherapeu... | endpts.com... |
| 12.08.2022 | House passes historic drug pricing reforms, lining up d... | In 2019, Aptinyx’s stock cratered after it reported that its lead candidate failed a diabetic nerve ... | endpts.com... |
| 10.11.2021 | Aptinyx Reports Third Quarter 2021 Financial Results and Rec... | Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights Completed enrollment in P... | marketscre... |
| 16.09.2021 | Aptinyx : Secures $50 Million Growth Capital Credit Facility... | Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative th... | marketscre... |
| 10.08.2021 | Aptinyx : Initiating CEO transition plan—effective January 1... | Initiating CEO transition plan-effective January 1, 2022, Aptinyx CEO Norbert Riedel will assume rol... | marketscre... |
| 10.03.2019 | Clinical trials of Allergan’s antidepressant rapastinel fail... | The three studies – RAP-MD-01, -02 and -03 – measured change over a three-week period in baseline me... | medcitynew... |
| 16.01.2019 | Aptinyx shares crater as lead drug fails in PhII neuropath... | Aptinyx’s approach to modulating the NMDA receptor to treat disorders of the central nerv... | endpts.com... |
| 03.12.2018 | 5 Startup Trends that Shaped the Midwest in 2018 1. Marketp... | 2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. J... | hpa.vc/5-s... |
| 29.11.2018 | 5 startup trends that shaped the Midwest in 2018 | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI an... | venturebea... |
| 29.11.2018 | 5 startup trends that shaped the Midwest in 2018 | 2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. J... | venturebea... |
Show more